Copyright
©The Author(s) 2023.
World J Hepatol. Sep 27, 2023; 15(9): 1021-1032
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1021
Published online Sep 27, 2023. doi: 10.4254/wjh.v15.i9.1021
Table 1 Biochemical classification of drug-induced liver injury
| Hepatocellular DILI | Mixed DILI | Cholestatic DILI | |
| AASLD criteria for diagnosis of DILI | Elevation of ALT ≥ 3 times ULN and ALT/ALP ratio ≥ 5 times | ALT ≥ 3 times ULN, ALP ≥ 2 times ULN and ALT/ALP ratio < 5 but >2 times ULN | ALP ≥ 2 times ULN and ALT/ALP ratio of ≤ 2 times ULN |
| R value criteria for different patterns of DILI | R = (ALT/ULN)/(ALP/ULN) > 5 | R = (ALT/ULN)/(ALP/ULN) < 5 and > 2 | R = (ALT/ULN)/(ALP/ULN) < 2 |
- Citation: Purwar S, Fatima A, Bhattacharyya H, Simhachalam Kutikuppala LV, Cozma MA, Srichawla BS, Komer L, Nurani KM, Găman MA. Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms. World J Hepatol 2023; 15(9): 1021-1032
- URL: https://www.wjgnet.com/1948-5182/full/v15/i9/1021.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i9.1021